Get informed when a big investor buys or sells
+ FollowLoading insider trades…
Loading congress trades…
| Market cap | $1.37 Billion |
|---|---|
| Enterprise Value | $1.58 Billion |
| Annual dividend | $2.16 |
| Earnings per Share | $-0.14 |
| Beta | 0.14 |
| Outstanding Shares | 37,350,401 |
| P/E Ratio | -28.45 |
|---|---|
| PEG | 6.38 |
| Price to Sales | 3.66 |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | 5.75 |
| Enterprise Value to EBIT | -68.33 |
| Enterprise Value to Net Income | -43 |
| Total Debt to Enterprise | 0.19 |
| Debt to Equity | 19.79 |
No data
No data available for the latest quarter.
No data available for the latest quarter.
Harrow Health, Inc. owns a portfolio of ophthalmic pharmaceutical businesses, including ImprimisRx, the nation's leading ophthalmology outsourcing facility and pharmaceutical compounding business. The company holds large equity positions...
Stockcircle shows 4 open-market insider purchases and 1 open-market insider sale for Harrow- 8.625% NT REDEEM 30/04/2026 USD 25 in the last six months from SEC Form 4 reports by executives, directors, and other insiders.
Form 4 insider trades are added as new filings are imported. Top investor 13F holdings refresh after each quarterly filing cycle. Politician trade disclosures are added when new reports are published on Stockcircle.